<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes">
    <title>üéß Neurology Study Guide ‚Äî Audio Edition</title>
    <style>
        :root { --primary: #6366f1; --primary-light: #818cf8; --accent: #e07b53; --bg: #1a1a2e; --card-bg: #16213e; --text: #e8e8e8; --text-muted: #a0a0a0; --border: #2d3a4f; }
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); line-height: 1.8; padding: 20px; padding-bottom: 200px; font-size: 18px; }
        .header { text-align: center; padding: 30px 20px; background: linear-gradient(135deg, var(--primary), var(--primary-light)); border-radius: 16px; margin-bottom: 20px; }
        .header h1 { font-size: 1.5rem; margin-bottom: 8px; }
        .audio-controls { position: fixed; bottom: 0; left: 0; right: 0; background: rgba(22,33,62,0.98); padding: 15px 20px; padding-bottom: max(15px, env(safe-area-inset-bottom)); border-top: 1px solid var(--border); z-index: 1000; }
        .controls-row { display: flex; align-items: center; justify-content: center; gap: 15px; margin-bottom: 10px; }
        .control-btn { background: var(--primary); border: none; color: white; width: 50px; height: 50px; border-radius: 50%; font-size: 1.3rem; cursor: pointer; display: flex; align-items: center; justify-content: center; }
        .control-btn.play-btn { width: 65px; height: 65px; font-size: 1.6rem; background: var(--accent); }
        .progress-section { display: flex; align-items: center; gap: 10px; font-size: 0.8rem; color: var(--text-muted); }
        .progress-bar { flex: 1; height: 6px; background: var(--border); border-radius: 3px; cursor: pointer; }
        .progress-fill { height: 100%; background: var(--accent); width: 0%; }
        .current-topic { text-align: center; font-size: 0.85rem; color: var(--accent); margin-top: 8px; }
        .settings-row { display: flex; justify-content: center; gap: 20px; margin-top: 10px; }
        .speed-control select, .pause-control select { background: var(--card-bg); color: var(--text); border: 1px solid var(--border); padding: 6px 10px; border-radius: 8px; }
        .section { background: var(--card-bg); border-radius: 12px; margin-bottom: 20px; }
        .section-header { background: var(--primary); padding: 15px 20px; font-size: 1.1rem; font-weight: 600; display: flex; justify-content: space-between; }
        .section-content { padding: 20px; }
        .topic { margin-bottom: 25px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
        .topic:last-child { border-bottom: none; }
        .topic-title { font-size: 1.1rem; font-weight: 600; color: var(--accent); margin-bottom: 15px; }
        .content-block { margin-bottom: 15px; padding: 15px; background: rgba(255,255,255,0.03); border-radius: 8px; border-left: 3px solid var(--primary); }
        .content-block.high-yield { border-left-color: #ef4444; background: rgba(239, 68, 68, 0.1); }
        .block-label { font-size: 0.75rem; text-transform: uppercase; color: var(--text-muted); margin-bottom: 8px; }
        .current { background: rgba(99, 102, 241, 0.3); border-radius: 3px; }
        .voice-selector { margin: 15px 0; padding: 15px; background: var(--card-bg); border-radius: 12px; }
        .voice-selector select { width: 100%; padding: 10px; background: var(--bg); color: var(--text); border: 1px solid var(--border); border-radius: 8px; }
        .toc { background: var(--card-bg); border-radius: 12px; padding: 20px; margin-bottom: 20px; }
        .toc-item { padding: 10px 15px; margin: 5px 0; background: rgba(255,255,255,0.03); border-radius: 8px; cursor: pointer; display: flex; justify-content: space-between; }
        .toc-item.active { background: var(--primary); }
    </style>
</head>
<body>
<div class="header"><h1>üß† Neurology Study Guide</h1><p>Audio Edition ‚Ä¢ ABIM Board Review ‚Ä¢ 6% of Exam</p><p style="font-size:0.8rem; opacity:0.7; margin-top:8px;">v1.0 BUILD #8</p></div>
<div class="voice-selector"><label>üéôÔ∏è Voice:</label><select id="voiceSelect"></select></div>
<div class="toc"><h2>üìã Chapters</h2>
    <div class="toc-item" data-section="0"><span>1. Stroke</span><span>~8 min</span></div>
    <div class="toc-item" data-section="1"><span>2. Seizures & Epilepsy</span><span>~6 min</span></div>
    <div class="toc-item" data-section="2"><span>3. Headache</span><span>~5 min</span></div>
    <div class="toc-item" data-section="3"><span>4. Movement Disorders</span><span>~5 min</span></div>
    <div class="toc-item" data-section="4"><span>5. Dementia</span><span>~5 min</span></div>
    <div class="toc-item" data-section="5"><span>6. Neuromuscular Disorders</span><span>~6 min</span></div>
</div>
<div id="audioContent">
<div class="section" data-section="0">
    <div class="section-header"><span>1. Stroke</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Acute Ischemic Stroke</div>
            <div class="content-block high-yield"><div class="block-label">Time Windows</div>
                <p class="speakable">IV alteplase is indicated within 4.5 hours of symptom onset or last known well time.</p>
                <p class="speakable">Exclusions for the 3 to 4.5 hour window include age over 80, severe stroke with NIHSS greater than 25, diabetes with prior stroke, and oral anticoagulant use.</p>
                <p class="speakable">Blood pressure must be below 185/110 before and below 180/105 for 24 hours after thrombolysis.</p>
                <p class="speakable">Thrombectomy can extend the window up to 24 hours in selected patients with salvageable penumbra on perfusion imaging.</p>
            </div>
            <div class="content-block high-yield"><div class="block-label">Contraindications to tPA</div>
                <p class="speakable">Absolute contraindications include recent head trauma or stroke within 3 months, intracranial hemorrhage, intracranial neoplasm, and active bleeding.</p>
                <p class="speakable">Blood glucose must be above 50. Platelets must be above 100,000. INR must be below 1.7.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Secondary Prevention</div>
            <div class="content-block"><div class="block-label">Antiplatelet Therapy</div>
                <p class="speakable">Aspirin 160 to 325 milligrams should be started within 24 to 48 hours.</p>
                <p class="speakable">Dual antiplatelet therapy with aspirin plus clopidogrel for 21 days is indicated for minor stroke or high-risk TIA based on the POINT and CHANCE trials.</p>
                <p class="speakable">Long-term therapy is aspirin or clopidogrel monotherapy.</p>
            </div>
            <div class="content-block high-yield"><div class="block-label">Atrial Fibrillation</div>
                <p class="speakable">Stroke from atrial fibrillation requires anticoagulation, not antiplatelet therapy.</p>
                <p class="speakable">DOACs are preferred over warfarin for non-valvular AF.</p>
                <p class="speakable">Timing of anticoagulation after stroke depends on infarct size. Small strokes can start at 1 to 3 days, large strokes at 7 to 14 days.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Hemorrhagic Stroke</div>
            <div class="content-block"><div class="block-label">Management</div>
                <p class="speakable">Intracerebral hemorrhage requires blood pressure control. Target systolic 140 to 160 for most patients.</p>
                <p class="speakable">Reverse anticoagulation immediately. 4-factor PCC for warfarin, idarucizumab for dabigatran, andexanet for Xa inhibitors.</p>
                <p class="speakable">Neurosurgical consultation for large hemorrhages or cerebellar hemorrhage greater than 3 centimeters.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="1">
    <div class="section-header"><span>2. Seizures & Epilepsy</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Status Epilepticus</div>
            <div class="content-block high-yield"><div class="block-label">Management Algorithm</div>
                <p class="speakable">Status epilepticus is seizure lasting more than 5 minutes or recurrent seizures without return to baseline.</p>
                <p class="speakable">First-line treatment is IV benzodiazepine: lorazepam 4 milligrams or diazepam 10 milligrams or midazolam IM if no IV access.</p>
                <p class="speakable">Second-line is IV antiepileptic: fosphenytoin, valproate, or levetiracetam.</p>
                <p class="speakable">Refractory status requires continuous infusion of midazolam, propofol, or pentobarbital with EEG monitoring.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Epilepsy Treatment</div>
            <div class="content-block"><div class="block-label">Drug Selection</div>
                <p class="speakable">For focal seizures, options include levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, and lacosamide.</p>
                <p class="speakable">For generalized seizures, options include valproate, levetiracetam, and lamotrigine.</p>
                <p class="speakable">Avoid carbamazepine and phenytoin in generalized epilepsy as they can worsen absence and myoclonic seizures.</p>
                <p class="speakable">Lamotrigine and levetiracetam are preferred in women of childbearing age. Valproate is teratogenic.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="2">
    <div class="section-header"><span>3. Headache</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Migraine</div>
            <div class="content-block"><div class="block-label">Treatment</div>
                <p class="speakable">Acute treatment includes NSAIDs, acetaminophen, triptans, and antiemetics. Triptans are contraindicated in coronary artery disease.</p>
                <p class="speakable">Prophylaxis is indicated for frequent migraines. Options include beta-blockers, topiramate, valproate, and amitriptyline.</p>
                <p class="speakable">CGRP monoclonal antibodies like erenumab and fremanezumab are newer prophylactic options for refractory cases.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Secondary Headaches</div>
            <div class="content-block high-yield"><div class="block-label">Red Flags</div>
                <p class="speakable">Thunderclap headache with sudden severe onset requires evaluation for subarachnoid hemorrhage. CT head then LP if CT negative.</p>
                <p class="speakable">New headache over age 50 raises concern for giant cell arteritis or mass lesion.</p>
                <p class="speakable">Headache with fever and neck stiffness suggests meningitis. Papilledema suggests elevated intracranial pressure.</p>
                <p class="speakable">Headache worse with Valsalva or positional changes may indicate mass lesion or CSF leak.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="3">
    <div class="section-header"><span>4. Movement Disorders</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Parkinson Disease</div>
            <div class="content-block high-yield"><div class="block-label">Diagnosis and Treatment</div>
                <p class="speakable">PD presents with bradykinesia plus resting tremor or rigidity. Asymmetric onset is typical.</p>
                <p class="speakable">Carbidopa-levodopa is the most effective treatment for motor symptoms.</p>
                <p class="speakable">Dopamine agonists like pramipexole and ropinirole are alternatives, especially in younger patients to delay levodopa.</p>
                <p class="speakable">MAO-B inhibitors selegiline and rasagiline can be used as monotherapy or adjuncts.</p>
                <p class="speakable">Deep brain stimulation is considered for motor fluctuations refractory to medication optimization.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Essential Tremor</div>
            <div class="content-block"><div class="block-label">Key Features</div>
                <p class="speakable">Essential tremor is an action tremor, present with movement and posture, not at rest.</p>
                <p class="speakable">Often bilateral and symmetric, affecting hands, head, and voice.</p>
                <p class="speakable">Improves with alcohol, which is a helpful diagnostic clue.</p>
                <p class="speakable">Treatment is propranolol or primidone.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="4">
    <div class="section-header"><span>5. Dementia</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Dementia Types</div>
            <div class="content-block"><div class="block-label">Key Differences</div>
                <p class="speakable">Alzheimer disease is the most common dementia. Gradual onset with prominent memory impairment early. Hippocampal atrophy on MRI.</p>
                <p class="speakable">Vascular dementia has stepwise progression often with focal neurologic signs. Risk factors are stroke and cardiovascular disease.</p>
                <p class="speakable">Lewy body dementia has visual hallucinations, parkinsonism, and fluctuating cognition. Avoid antipsychotics due to severe sensitivity.</p>
                <p class="speakable">Frontotemporal dementia presents with personality changes and behavioral disinhibition. Onset typically before age 65.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Treatment</div>
            <div class="content-block"><div class="block-label">Medications</div>
                <p class="speakable">Cholinesterase inhibitors donepezil, rivastigmine, and galantamine are used for mild to moderate Alzheimer disease.</p>
                <p class="speakable">Memantine, an NMDA antagonist, is added for moderate to severe disease.</p>
                <p class="speakable">These medications provide modest symptomatic benefit but do not halt disease progression.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="5">
    <div class="section-header"><span>6. Neuromuscular Disorders</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Myasthenia Gravis</div>
            <div class="content-block high-yield"><div class="block-label">Key Points</div>
                <p class="speakable">MG presents with fatigable weakness, worse with use and better with rest. Ptosis, diplopia, and bulbar symptoms are common.</p>
                <p class="speakable">Anti-AChR antibodies are positive in 85 percent. Anti-MuSK antibodies in some seronegative cases.</p>
                <p class="speakable">Ice pack test: ptosis improves with cooling.</p>
                <p class="speakable">Treatment is pyridostigmine for symptomatic relief. Immunosuppression with steroids and steroid-sparing agents for most patients.</p>
                <p class="speakable">Thymectomy is indicated for thymoma and considered for generalized MG even without thymoma.</p>
            </div>
            <div class="content-block high-yield"><div class="block-label">Myasthenic Crisis</div>
                <p class="speakable">Myasthenic crisis is respiratory failure from MG. Check FVC every 4 hours. Intubate if FVC falls below 15 to 20 mL per kg.</p>
                <p class="speakable">Treatment is IVIG or plasmapheresis.</p>
                <p class="speakable">Avoid aminoglycosides, fluoroquinolones, and beta-blockers as they can worsen MG.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Guillain-Barr√© Syndrome</div>
            <div class="content-block high-yield"><div class="block-label">Key Points</div>
                <p class="speakable">GBS is acute inflammatory demyelinating polyneuropathy presenting with ascending weakness and areflexia.</p>
                <p class="speakable">Often follows infection, classically Campylobacter jejuni.</p>
                <p class="speakable">CSF shows albuminocytologic dissociation: elevated protein with normal cell count.</p>
                <p class="speakable">Treatment is IVIG or plasmapheresis. Steroids are not effective.</p>
                <p class="speakable">Monitor for respiratory failure. FVC less than 20 mL per kg or declining trend warrants ICU monitoring.</p>
            </div>
        </div>
    </div>
</div>
</div>
<div class="audio-controls">
    <div class="controls-row"><button class="control-btn" onclick="skipBackward()">‚è™</button><button class="control-btn play-btn" id="playPauseBtn" onclick="togglePlayPause()">‚ñ∂Ô∏è</button><button class="control-btn" onclick="skipForward()">‚è©</button><button class="control-btn" onclick="stopReading()">‚èπÔ∏è</button></div>
    <div class="progress-section"><span id="currentTime">0:00</span><div class="progress-bar" onclick="seekTo(event)"><div class="progress-fill" id="progressFill"></div></div><span id="totalTime">0:00</span></div>
    <div class="current-topic" id="currentTopic">Ready to play</div>
    <div class="settings-row"><div class="speed-control"><label>Speed:</label><select id="speedSelect" onchange="updateSpeed()"><option value="0.75">0.75√ó</option><option value="1" selected>1√ó</option><option value="1.5">1.5√ó</option><option value="2">2√ó</option></select></div><div class="pause-control"><label>Pauses:</label><select id="pauseSelect" onchange="updatePauses()"><option value="short">Short</option><option value="medium" selected>Medium</option><option value="long">Long</option></select></div></div>
</div>
<script>
let isPlaying=false,currentSentenceIndex=0,sentences=[],speechRate=1,englishVoices=[],pauseSettings={sentence:400,paragraph:800,section:1500};
document.addEventListener('DOMContentLoaded',()=>{loadVoices();buildSentenceList();setupTOC();const s=localStorage.getItem('neuro_audio_pos');if(s)currentSentenceIndex=parseInt(s)||0;});
function loadVoices(){const sel=document.getElementById('voiceSelect');function pop(){const all=speechSynthesis.getVoices();englishVoices=all.filter(v=>v.lang.startsWith('en-'));if(!englishVoices.length){setTimeout(pop,100);return;}sel.innerHTML='';englishVoices.forEach((v,i)=>{const o=document.createElement('option');o.value=i;o.textContent=`${v.localService?'‚≠ê ':''}${v.name}`;sel.appendChild(o);});}pop();speechSynthesis.onvoiceschanged=pop;}
function buildSentenceList(){sentences=[];document.querySelectorAll('.speakable').forEach((el,i,arr)=>{const sec=el.closest('.section'),top=el.closest('.topic');sentences.push({text:el.textContent.trim(),element:el,section:sec?parseInt(sec.dataset.section):0,topic:top?.querySelector('.topic-title')?.textContent||'',isNewBlock:i===0||el.closest('.content-block')!==arr[i-1]?.closest('.content-block'),isNewSection:i===0||(sec?.dataset.section!==arr[i-1]?.closest('.section')?.dataset.section)});});updateProgress();}
function setupTOC(){document.querySelectorAll('.toc-item').forEach(item=>{item.addEventListener('click',()=>jumpToSection(parseInt(item.dataset.section)));});}
function jumpToSection(idx){const i=sentences.findIndex(s=>s.section===idx);if(i!==-1){currentSentenceIndex=i;if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}}
function togglePlayPause(){isPlaying?pauseReading():startReading();}
function startReading(){isPlaying=true;document.getElementById('playPauseBtn').textContent='‚è∏Ô∏è';speakCurrentSentence();}
function pauseReading(){isPlaying=false;speechSynthesis.cancel();document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';localStorage.setItem('neuro_audio_pos',currentSentenceIndex);}
function stopReading(){isPlaying=false;speechSynthesis.cancel();currentSentenceIndex=0;document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';updateProgress();localStorage.removeItem('neuro_audio_pos');}
function speakCurrentSentence(){if(!isPlaying||currentSentenceIndex>=sentences.length){if(currentSentenceIndex>=sentences.length)stopReading();return;}const s=sentences[currentSentenceIndex],u=new SpeechSynthesisUtterance(s.text),vi=parseInt(document.getElementById('voiceSelect').value)||0;if(englishVoices[vi])u.voice=englishVoices[vi];u.lang='en-US';u.rate=speechRate;document.querySelectorAll('.current').forEach(el=>el.classList.remove('current'));s.element.classList.add('current');s.element.scrollIntoView({behavior:'smooth',block:'center'});document.getElementById('currentTopic').textContent=s.topic;updateProgress();u.onend=()=>{currentSentenceIndex++;if(currentSentenceIndex<sentences.length){let p=pauseSettings.sentence;if(sentences[currentSentenceIndex].isNewSection)p=pauseSettings.section;else if(sentences[currentSentenceIndex].isNewBlock)p=pauseSettings.paragraph;setTimeout(()=>{if(isPlaying)speakCurrentSentence();},p);}else stopReading();};speechSynthesis.speak(u);}
function updateProgress(){const pct=sentences.length?(currentSentenceIndex/sentences.length)*100:0;document.getElementById('progressFill').style.width=pct+'%';const avg=3/speechRate;document.getElementById('currentTime').textContent=Math.floor(currentSentenceIndex*avg/60)+':'+(Math.floor(currentSentenceIndex*avg)%60).toString().padStart(2,'0');document.getElementById('totalTime').textContent=Math.floor(sentences.length*avg/60)+':'+(Math.floor(sentences.length*avg)%60).toString().padStart(2,'0');}
function seekTo(e){currentSentenceIndex=Math.floor((e.offsetX/e.currentTarget.offsetWidth)*sentences.length);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipForward(){currentSentenceIndex=Math.min(currentSentenceIndex+10,sentences.length-1);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipBackward(){currentSentenceIndex=Math.max(currentSentenceIndex-10,0);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function updateSpeed(){speechRate=parseFloat(document.getElementById('speedSelect').value);updateProgress();}
function updatePauses(){const s=document.getElementById('pauseSelect').value;pauseSettings=s==='short'?{sentence:200,paragraph:400,section:800}:s==='long'?{sentence:600,paragraph:1200,section:2000}:{sentence:400,paragraph:800,section:1500};}
</script>
</body>
</html>
